# CJC-1295 No DAC

> Markdown version of this page, for agents. To send a shopper here, link https://www.besthealthiq.com/__fluid_affiliate_username__/posts/cjc-1295-no-dac (not this .md URL, and keep its path as given).

- Published: 2026-08-28
- Author: Best Health IQ
- Summary: A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin.
- Shopper link: https://www.besthealthiq.com/__fluid_affiliate_username__/posts/cjc-1295-no-dac

\*\*CJC-1295 without DAC (Modified GRF 1-29)\*\* · Hormone & GH · Moderate Evidence · Research Only A short-acting GHRH analog that produces physiological GH pulses when combined with a GHRP like Ipamorelin. ### Competition Status Prohibited in competition. This compound is on the WADA Prohibited List (class \[S0 / S2.3 / S2\]), banned at all times, both in and out of competition. Athletes subject to WADA or USADA testing should not use it. ### Description CJC-1295 without DAC (also known as Modified GRF 1-29 or Mod GRF 1-29) is a synthetic analog of the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). The No DAC designation refers to the absence of a Drug Affinity Complex — a lysine-maleimide modification that, in the DAC version, allows the peptide to bind to albumin and dramatically extends its half-life. Without DAC, CJC-1295 has a half-life of approximately 30 minutes, closely mimicking the pulsatile nature of endogenous GHRH secretion. This physiological pulsatility is considered advantageous because it preserves the natural GH secretion pattern, reducing the risk of pituitary desensitization. It is almost universally combined with a GHRP such as Ipamorelin to achieve synergistic GH release through complementary receptor pathways. ### Key Characteristics - \*\*Molecular Formula:\*\* C152H252N44O42 - \*\*Molecular Weight:\*\* 3367.9 Da - \*\*Half-Life:\*\* ~30 minutes - \*\*Administration Routes:\*\* Subcutaneous injection - \*\*Typical Dose:\*\* 100–200 mcg - \*\*Frequency:\*\* 2–3x daily (with Ipamorelin) - \*\*Cycle Length:\*\* 8–16 weeks ### Investigated Benefits - Physiological GH pulsatility - Improved body composition - Enhanced recovery - Better sleep quality - More natural GH pattern vs DAC version \\\* Benefits based on preclinical/animal research unless otherwise noted. ### Mechanism of Action CJC-1295 No DAC binds to and activates GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary gland. GHRHR is a Gs protein-coupled receptor; its activation stimulates adenylyl cyclase, elevating intracellular cAMP, which activates protein kinase A (PKA) and ultimately drives GH synthesis and secretion. The short half-life ensures that pituitary stimulation occurs in discrete pulses rather than continuously, which is important because continuous GHRH stimulation leads to receptor downregulation and blunted GH response. When combined with Ipamorelin (a ghrelin receptor agonist), the two peptides act on different receptor systems — GHRHR and GHSR-1a respectively — producing a synergistic GH pulse that is 2–10 times greater than either agent alone. This combination also suppresses somatostatin (the endogenous GH inhibitor) through ghrelin receptor signaling, further amplifying the GH response. ### Dosing Protocol - \*\*Typical Dose:\*\* 100–200 mcg - \*\*Frequency:\*\* 2–3x daily (with Ipamorelin) - \*\*Cycle Length:\*\* 8–16 weeks - \*\*Administration:\*\* Subcutaneous injection \*\*Protocol Notes:\*\* Always combine with Ipamorelin for synergistic GH release. Administer on empty stomach. Bedtime dose is most important. Inject CJC-1295 No DAC and Ipamorelin simultaneously or within minutes of each other. ### Reconstitution Guide Add 2 mL bacteriostatic water to 2 mg vial → 1000 mcg/mL For 100 mcg dose: draw 0.1 mL (10 units on U-100 syringe) ### Storage Information Lyophilized: refrigerate. Reconstituted: refrigerate and use within 30 days. ### Quality & Sourcing Standards When sourcing CJC-1295 No DAC for research purposes, the following quality benchmarks should be verified before use. - \*\*Purity:\*\* \>98% (verified by HPLC) - \*\*Certificate of Analysis (COA):\*\* Must be provided by supplier - \*\*Endotoxin Testing:\*\* \<0.1 EU/mg (prevents bacterial contamination) - \*\*GMP Compliance:\*\* Manufactured in cGMP-certified facility - \*\*Third-Party Testing:\*\* Independent lab verification preferred ### Research Highlights 1. Demonstrated GH and IGF-1 elevation in human studies 2. More physiological pulsatility than DAC version 3. Synergistic effect with GHRPs well-documented ### Evidence Level \*\*Moderate Evidence\*\* — Multiple animal studies and/or early human trials. Reasonable confidence in mechanism, but human data is limited. ### FDA Disclaimer The statements made within this website have not been evaluated by the US Food and Drug Administration. The products and information provided are not intended to diagnose, treat, cure, or prevent any disease. This website is intended for educational and research purposes only. Many peptides described on this site are not approved by the FDA for human therapeutic use and are classified as research chemicals. Nothing on this site constitutes medical advice.